

2° Convegno Nazionale

IL TEAM INTERDISCIPLINARE NEL CARCINOMA DELLA PROSTATA

NEGRAR DI VALPOLICELLA 6-7 DICEMBRE 2019

Sala Perez - IRCCS Ospedale Sacro Cuore Don Calabria



**La malattia organo
confinata: carcinoma
prostatico ad alto rischio.**

CASO CLINICO



Carlo Messina, MD

**U.O.C. Oncologia Medica
Ospedale S. Chiara,
Trento**

carlo.messina@apss.tn.it

Clinical presentation

- ✓ 56 year old patient
- ✓ No remarkable past medical history
- ✓ **PSA baseline 20 ng/ml**
- ✓ Rectal exploration revealed a suspicious prostatic nodule
- ✓ US-trans rectal prostate biopsy: 12/16 + specimens for adenocarcinoma
Gleason score 8= 4+4
- ✓ Pelvic MRI: **likely cT3**
- ✓ Bone scan and CT scan were negative for local and distant mets



Clinical presentation

Overall Clinical stage:

- PSA= 20 ng/ml
- cT3 N0 M0
- Gleason score: 8=4+4

Radical prostatectomy or radiotherapy \mp ADT for high risk localized prostate cancer....
This is the dilemma....

Risk groups for localized prostate cancer¹:

Low risk	T1-T2a and GS \leq 6 and PSA \leq 10
Intermediate risk	T2b and/or GS7 and/or PSA10-20
High risk	\geq T2c or GS8-10 or PSA >20

GS, Gleason score; PSA, prostate-specific antigen.



Case presentation

Pathological Clinical stage:

- pT3b N+ 2/16 M0 R0
- Gleason score: 8=4+4
- Post-op PSA= 1 ng/ml
- Post-op PET choline: negative
- **Locally advanced disease**



Radiotherapy \mp ADT or
upfront ADT....
This is the dilemma....



Tumour board opinion: RT + ADT



Case presentation

- PSA= 0.04 ng/ml at 3 and 6 months after salvage RT + ADT
- PSA = 1,5 ng/ml after 18 months of ADT confirmed in two consecutive PSA measurement.
- Bicalutamide 50 mg was added to ADT
- PSA= 2 ng/ ml and 3 ng/ml at 3 and 6 months of CAD
- CT scan, bone scan and PET choline: negative for local and distant metastasis




Who are nmCRPC patients?

PSA Doubling time predicts outcomes in nmCRPC




1. Paller CJ et al. *Clin Adv Hematol Oncol*. 2013;11(1):14-23; 2. Arlen PM, et al. *J Urol*. 2008 Jun;179(6):2181-5; 3. Smith MR, et al. *J Clin Oncol*. 2013 Oct 20;31(30):3800-6; 4. Freedland SJ, et al. *J Clin Oncol*. 2007 May 1;25(13):1765-71; 5. Howard LE et al. *BJU Int*. 2017 Nov;120(5B):E80-E86.

Phase III randomized trials in High-Risk nmCRPC




Similar trials with Enzalutamide (PROSPER)¹, Apalutamide (SPARTAN)², Darolutamide (ARAMIS)³

Metastasis-Free survival




Enzalutamide


Apalutamide



Darolutamide



**The patient received apalutamide 240 mg daily as
compassionate use program....**



**...CT scan and bone scan were
performed every 16 weeks...**



**...No evidence of disease
recurrence with
conventional imaging at 12
months...**

**...The treatment has been well tolerated and he is
keeping on treatment with apalutamide 240 mg ...**